Neumora Therapeutics Inc.... (NMRA)
Neumora Therapeutics Common Stock Statistics
Share Statistics
Neumora Therapeutics Common Stock has 161.98M shares outstanding. The number of shares has increased by 1.68% in one year.
| Shares Outstanding | 161.98M |
| Shares Change (YoY) | 1.68% |
| Shares Change (QoQ) | 0.96% |
| Owned by Institutions (%) | 50.43% |
| Shares Floating | 56M |
| Failed to Deliver (FTD) Shares | 21.39K |
| FTD / Avg. Volume | 0.64% |
Short Selling Information
The latest short interest is 11.03M, so 6.83% of the outstanding shares have been sold short.
| Short Interest | 11.03M |
| Short % of Shares Out | 6.83% |
| Short % of Float | 19.99% |
| Short Ratio (days to cover) | 1.84 |
Valuation Ratios
The PE ratio is -6.93 and the forward PE ratio is -1.26. Neumora Therapeutics Common Stock's PEG ratio is -2.58.
| PE Ratio | -6.93 |
| Forward PE | -1.26 |
| PS Ratio | 0 |
| Forward PS | 0.6 |
| PB Ratio | 5.89 |
| P/FCF Ratio | -9.23 |
| PEG Ratio | -2.58 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Neumora Therapeutics Inc. Common Stock.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.51, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.51 |
| Quick Ratio | 10.51 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.64 |
| Cash Flow / Debt | -98.72 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.85% and return on capital (ROIC) is -91.26%.
| Return on Equity (ROE) | -0.85% |
| Return on Assets (ROA) | -0.77% |
| Return on Capital (ROIC) | -91.26% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2,216,245.45 |
| Employee Count | 110 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 178K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -91.52% in the last 52 weeks. The beta is 2.6, so Neumora Therapeutics Common Stock's price volatility has been higher than the market average.
| Beta | 2.6 |
| 52-Week Price Change | -91.52% |
| 50-Day Moving Average | 1.74 |
| 200-Day Moving Average | 8.91 |
| Relative Strength Index (RSI) | 25.98 |
| Average Volume (20 Days) | 3.32M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -263.46M |
| Net Income | -243.79M |
| EBITDA | -263.46M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.53 |
Balance Sheet
The company has 142.15M in cash and 1.85M in debt, giving a net cash position of 140.29M.
| Cash & Cash Equivalents | 142.15M |
| Total Debt | 1.85M |
| Net Cash | 140.29M |
| Retained Earnings | -947.22M |
| Total Assets | 316.97M |
| Working Capital | 284.17M |
Cash Flow
In the last 12 months, operating cash flow was -182.94M and capital expenditures 0, giving a free cash flow of -182.94M.
| Operating Cash Flow | -182.94M |
| Capital Expenditures | 0 |
| Free Cash Flow | -182.94M |
| FCF Per Share | -1.15 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NMRA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -136.61% |
| FCF Yield | -100.39% |
Analyst Forecast
The average price target for NMRA is $7, which is 525% higher than the current price. The consensus rating is "Hold".
| Price Target | $7 |
| Price Target Difference | 525% |
| Analyst Consensus | Hold |
| Analyst Count | 8 |
Scores
| Altman Z-Score | -1.89 |
| Piotroski F-Score | 1 |